JP2021519794A5 - - Google Patents
Info
- Publication number
- JP2021519794A5 JP2021519794A5 JP2020553520A JP2020553520A JP2021519794A5 JP 2021519794 A5 JP2021519794 A5 JP 2021519794A5 JP 2020553520 A JP2020553520 A JP 2020553520A JP 2020553520 A JP2020553520 A JP 2020553520A JP 2021519794 A5 JP2021519794 A5 JP 2021519794A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862651512P | 2018-04-02 | 2018-04-02 | |
| US62/651,512 | 2018-04-02 | ||
| PCT/US2019/025165 WO2019195159A1 (en) | 2018-04-02 | 2019-04-01 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021519794A JP2021519794A (ja) | 2021-08-12 |
| JP2021519794A5 true JP2021519794A5 (https=) | 2022-04-07 |
| JPWO2019195159A5 JPWO2019195159A5 (https=) | 2022-04-07 |
| JP7337833B2 JP7337833B2 (ja) | 2023-09-04 |
Family
ID=68054774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020553520A Active JP7337833B2 (ja) | 2018-04-02 | 2019-04-01 | 縮合二環式Ｃ５ａＲアンタゴニストのプロドラッグ |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20190300526A1 (https=) |
| EP (1) | EP3773563B1 (https=) |
| JP (1) | JP7337833B2 (https=) |
| KR (1) | KR102809631B1 (https=) |
| CN (1) | CN111954525B (https=) |
| AR (1) | AR114464A1 (https=) |
| AU (1) | AU2019246969B2 (https=) |
| BR (1) | BR112020019822A2 (https=) |
| CA (1) | CA3095184A1 (https=) |
| ES (1) | ES2993034T3 (https=) |
| IL (1) | IL277608B2 (https=) |
| MA (1) | MA52245A (https=) |
| MX (1) | MX2020010390A (https=) |
| SG (1) | SG11202009588PA (https=) |
| TW (1) | TWI827590B (https=) |
| WO (1) | WO2019195159A1 (https=) |
| ZA (1) | ZA202006154B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018222601A1 (en) | 2017-05-31 | 2018-12-06 | Chemocentryx, Inc. | 5-5 FUSED RINGS AS C5a INHIBITORS |
| CN110997674B (zh) | 2017-05-31 | 2022-12-20 | 凯莫森特里克斯股份有限公司 | 作为C5a抑制剂的6-5稠合环类 |
| US11542256B2 (en) | 2017-09-03 | 2023-01-03 | Angion Biomedica Corp. | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors |
| MX2020006460A (es) | 2017-12-22 | 2020-11-06 | Chemocentryx Inc | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. |
| ES2980175T3 (es) | 2017-12-22 | 2024-09-30 | Chemocentryx Inc | Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR |
| WO2019195159A1 (en) | 2018-04-02 | 2019-10-10 | Chemocentryx, Inc. | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
| CN114072403A (zh) * | 2019-05-07 | 2022-02-18 | 百时美施贵宝公司 | 前药化合物 |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| JP7679383B2 (ja) * | 2019-12-19 | 2025-05-19 | ジェンフィット | ＲＯＲγモジュレーターのホスフェート誘導体及びその使用 |
| PL3886858T3 (pl) | 2019-12-19 | 2022-08-29 | Active Biotech Ab | Związki do leczenia chorób oka związanych z nadmiernym unaczynieniem |
| CN119841865A (zh) | 2020-02-07 | 2025-04-18 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US20220047592A1 (en) * | 2020-08-13 | 2022-02-17 | Chemocentryx, Inc. | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS |
| EP4211139A4 (en) | 2020-09-10 | 2024-12-18 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| EP4219453A4 (en) * | 2020-09-28 | 2024-10-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | PYRAZOLE COMPOUND AND ITS PREPARATION METHOD AND ITS USE |
| EP4262800A4 (en) * | 2020-12-21 | 2024-11-20 | ChemoCentryx, Inc. | TREATMENT OF C3 GLOMERULOPATHY WITH A C5A INHIBITOR |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CN114933584B (zh) * | 2021-08-09 | 2022-12-27 | 上海贵之言医药科技有限公司 | 一种二氢-2h-异吲哚酯类化合物 |
| WO2023066371A1 (zh) | 2021-10-22 | 2023-04-27 | 江苏恒瑞医药股份有限公司 | 含氮的四环化合物、其制备方法及其在医药上的应用 |
| CN113666985A (zh) * | 2021-10-22 | 2021-11-19 | 山东谷雨春生物科技有限公司 | 一种曲安奈德的制备方法 |
| CN116023321B (zh) * | 2022-12-30 | 2024-11-29 | 中国药科大学 | Sting抑制剂前药及其医药用途 |
| AU2024222719A1 (en) | 2023-02-16 | 2025-08-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| GB8613591D0 (en) | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| ES2349762T3 (es) | 2000-08-10 | 2011-01-11 | Pfizer Italia S.R.L. | Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden. |
| EP1322309B1 (en) | 2000-09-29 | 2008-08-13 | Neurogen Corporation | High affinity small molecule c5a receptor modulators |
| SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
| US7902179B2 (en) | 2001-04-26 | 2011-03-08 | Ajinomoto Co., Inc. | Heterocyclic compounds |
| DE10293174D2 (de) | 2001-07-19 | 2004-07-01 | Luk Lamellen & Kupplungsbau | Übertragungsstrecke zum Ansteuern einer Kupplung |
| ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| EP1487796A4 (en) | 2002-03-28 | 2005-11-16 | Neurogen Corp | SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR |
| AU2003218374A1 (en) | 2002-03-28 | 2003-10-13 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| WO2003084524A1 (en) | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| EP1534680B1 (en) | 2002-08-14 | 2012-02-22 | Pharmaco Investments, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| WO2004018460A1 (en) | 2002-08-21 | 2004-03-04 | Neurogen Corporation | Amino methyl imidazoles as c5a receptor modulators |
| ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| BRPI0909945A2 (pt) | 2008-06-20 | 2015-07-28 | Genentech Inc | "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase" |
| CA2965223C (en) | 2008-12-22 | 2019-09-24 | Chemocentryx, Inc. | C5ar antagonists |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| CA2771352A1 (en) | 2009-09-02 | 2011-03-10 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| PT2585064T (pt) | 2010-06-24 | 2017-08-08 | Chemocentryx Inc | Antagonistas do c5ar |
| US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| CA2882127A1 (en) | 2012-08-16 | 2014-02-20 | Janssen Pharmaceutica Nv | Pyrrolopyrazoles as n-type calcium channel blockers |
| CN103421006B (zh) | 2013-08-18 | 2016-06-22 | 上海师范大学 | 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用 |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| AU2017246228B2 (en) * | 2016-04-04 | 2021-04-15 | Chemocentryx, Inc. | Soluble C5aR antagonists |
| CN110997674B (zh) * | 2017-05-31 | 2022-12-20 | 凯莫森特里克斯股份有限公司 | 作为C5a抑制剂的6-5稠合环类 |
| WO2018222601A1 (en) * | 2017-05-31 | 2018-12-06 | Chemocentryx, Inc. | 5-5 FUSED RINGS AS C5a INHIBITORS |
| MX2020006460A (es) | 2017-12-22 | 2020-11-06 | Chemocentryx Inc | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. |
| ES2980175T3 (es) | 2017-12-22 | 2024-09-30 | Chemocentryx Inc | Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR |
| WO2019195159A1 (en) | 2018-04-02 | 2019-10-10 | Chemocentryx, Inc. | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
-
2019
- 2019-04-01 WO PCT/US2019/025165 patent/WO2019195159A1/en not_active Ceased
- 2019-04-01 US US16/371,627 patent/US20190300526A1/en not_active Abandoned
- 2019-04-01 BR BR112020019822-6A patent/BR112020019822A2/pt active Search and Examination
- 2019-04-01 AR ARP190100863A patent/AR114464A1/es unknown
- 2019-04-01 KR KR1020207031483A patent/KR102809631B1/ko active Active
- 2019-04-01 JP JP2020553520A patent/JP7337833B2/ja active Active
- 2019-04-01 ES ES19782402T patent/ES2993034T3/es active Active
- 2019-04-01 MA MA052245A patent/MA52245A/fr unknown
- 2019-04-01 CN CN201980024914.2A patent/CN111954525B/zh active Active
- 2019-04-01 EP EP19782402.2A patent/EP3773563B1/en active Active
- 2019-04-01 MX MX2020010390A patent/MX2020010390A/es unknown
- 2019-04-01 AU AU2019246969A patent/AU2019246969B2/en active Active
- 2019-04-01 IL IL277608A patent/IL277608B2/en unknown
- 2019-04-01 US US16/982,817 patent/US11608336B2/en active Active
- 2019-04-01 SG SG11202009588PA patent/SG11202009588PA/en unknown
- 2019-04-01 CA CA3095184A patent/CA3095184A1/en active Pending
- 2019-04-02 TW TW108111647A patent/TWI827590B/zh active
-
2020
- 2020-10-05 ZA ZA2020/06154A patent/ZA202006154B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519794A5 (https=) | ||
| JPWO2019195159A5 (https=) | ||
| ES2993034T3 (en) | Prodrugs of fused-bicyclic c5ar antagonists | |
| JP2017088633A5 (https=) | ||
| JP2013529647A5 (https=) | ||
| JP2018511647A5 (https=) | ||
| JP2021510692A5 (https=) | ||
| JP2007515432A5 (https=) | ||
| JP2008501000A5 (https=) | ||
| JP2012533533A (ja) | ピリジン−４−イル誘導体 | |
| WO2017035351A1 (en) | Amino compounds for treatment of medical disorders | |
| WO2017035355A1 (en) | Ether compounds for treatment of medical disorders | |
| JP2006524669A5 (https=) | ||
| CA2472713A1 (en) | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists | |
| JP2013527175A5 (https=) | ||
| JP2007525494A5 (https=) | ||
| CN105001165A (zh) | 取代的二氨基嘧啶其组合物，和用其治疗的方法 | |
| JPWO2022216971A5 (https=) | ||
| JP2020504746A5 (https=) | ||
| JP2019535723A5 (https=) | ||
| JP2016512227A (ja) | ピリジン−４−イル誘導体 | |
| JP2021512922A (ja) | ヘテロアリール化合物、それらの医薬組成物、及びそれら治療的使用 | |
| JP2010535706A5 (https=) | ||
| JP2018530582A5 (https=) | ||
| JP2012520271A5 (https=) |